The Anagnostou Lab https://validator.w3.org/feed/docs/rss2.html The Anagnostou Lab is here! Home Principal Investigator PlasmaCHORD, a novel machine learning model, distinguishes tumor-derived from clonal hematopoiesis-derived mutations in liquid biopsies routinely used in clinical cancer care ctDNA residual disease may provide a molecular green light for perioperative immunotherapy in individuals with resectable mesothelioma. Bridging liquid biopsy discoveries with clinical cancer: Harnessing ctDNA Molecular Response to Predict Clinical Outcomes and Guide Therapeutic Decision Making for Individuals with Lung Cancer. The Impostor Variants: Machine Learning Unmasks Clonal-Hematopoiesis Mutations in Liquid Biopsies Lab Members C3PO 2024 Postdoctoral Lecture Series Publications The revolutionary role of immunotherapy in the treatment of cancer Of Context, Quality, and Complexity: Fine-combing Tumor Mutational Burden in Immunotherapy-Treated Cancers Cancer evolution converging on common resistance mechanisms to PARP inhibition: A Molecular Tumor Board discussion. Can radiation help activate the immune system to fight cancer? How radioimmunotherapy affects immune response in patients with non-small cell lung cancer. 2025 Dedication of the Alex Grass Professor of Oncology Webinar on Early ctDNA Molecular Response Enhanced Through Integrated Analyses of Cell-Free DNA and Matched White Blood Cells.